Intellia Therapeutics (NTLA) Total Current Liabilities (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Total Current Liabilities data on file, last reported at $76.4 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities fell 32.11% year-over-year to $76.4 million in Q1 2026; TTM through Mar 2026 was $76.4 million, a 32.11% decrease from a year earlier, with the FY2025 full-year figure at $103.9 million, down 6.29% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $76.4 million, down from $103.9 million in the prior quarter.
• Over the last five years, Total Current Liabilities for NTLA reached as high as $131.1 million in Q3 2022 and fell as low as $76.4 million in Q1 2026.
• Historically, Total Current Liabilities has averaged $107.0 million across 5 years, with a median of $105.1 million in 2024.
• Across the five-year window, Total Current Liabilities surged 107.75% in 2022 and tumbled 32.11% in 2026, its largest moves.
• Year by year, Total Current Liabilities stood at $126.6 million in 2022, then retreated by 8.97% to $115.2 million in 2023, then fell by 3.78% to $110.9 million in 2024, then retreated by 6.29% to $103.9 million in 2025, then declined by 26.41% to $76.4 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $76.4 million in Q1 2026, $103.9 million in Q4 2025, and $93.7 million in Q3 2025.